Page last updated: 2024-09-05

diflomotecan and Cancer of Prostate

diflomotecan has been researched along with Cancer of Prostate in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bailly, C; Bigg, DC; Camara, J; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, PG; Lavergne, O; Lesueur-Ginot, L	1

Other Studies

1 other study(ies) available for diflomotecan and Cancer of Prostate

Article	Year
The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison. Anti-cancer drugs, 2001, Volume: 12, Issue:1 Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Cell Division; Cell-Free System; DNA; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Drug Stability; Enzyme Inhibitors; Female; Humans; Male; Mice; Mice, Nude; Osteonectin; Prostatic Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2001

Article

Year

The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.

Anti-cancer drugs, 2001, Volume: 12, Issue:1

Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Cell Division; Cell-Free System; DNA; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Drug Stability; Enzyme Inhibitors; Female; Humans; Male; Mice; Mice, Nude; Osteonectin; Prostatic Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2001